



Deadline	Wed 01 Aug 2018 13:00 EST Letter of Intent Wed 17 Oct 2018 13:00 EST Application
Call name	Komen Career Catalyst Research Grants FY2019 (Komen CCR Grants)
www	https://www.komen.org/ResearchGrants/FundingOpportunities.html
Focused on	Research career development of early career researchers & basic research of metastatic breast cancer disparities or data science to better understand and treat metastatic breast cancer
PI	Early career metastatic breast cancer researchers of any nationality anywhere in the world who have held faculty positions for no more than 5 years by the Application due date.
Eligible organisation	Non-profit research institutions anywhere in the world
Target group	Individual research team (graduate students, postdocs, technicians, collaborators) headed by a single PI (junior researcher) under supervision of a Lead Mentor & Mentor Committee Members
Expected outputs	Open Access (J) reviewed specialist articles; diagnosis & novel therapies for all stages of breast cancer
Call opens	Mon 02 Jul 2018
IOCB deadline	Mon 30 Jul 2018
Final deadline	Wed 01 Aug 2018 13:00 Eastern Standard Time Letter of Intent Wed 17 Oct 2018 13:00 EST Application
Evaluation results	Wed 22 Aug 2018 Letter of Intent decision Mon 15 Apr 2019 Final award notification
Signature of agreement	NA
Earliest date of implementation	NA
Latest date of implementation	NA
Sustainability	None
Reporting	Annual scientific progress report (3x), Interim scientific progress report, Final scientific progress report (1x), Annual financial report (3x), Interim financial report, Final financial report (1x)
Project duration (min-max)	Up to 36 months (3 years)
Allocation for the call	NA
Project budget (min-max)	Up to \$450,000 (\$150,000 per year)
Success rate	NA
Eligible costs	Direct costs: personnel costs, travel expenses, publication costs, coursework & training expenses, equipment costs (max 25% of total direct costs), goods & services Indirect costs & subcontracting: overheads max 25% of total direct costs
Reimbursement	100 %
Mode of funding	ex-ante
Language of application	English
Provider	Susan G. Komen, 5005 LBJ Freeway, Suite 526, Dallas, Texas 75244, US, www.komen.org www.komen.org/researchhelpdesk (program inquiries) +1 703 964 5840, pcsupport@altum.com (proposalCENTRAL technical inquiries)
Call identifier	Komen CCR Grants 2019
Call info	Komen CCR Grants FY2019 foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support up to 3 years of "protected" time for research career development (independent funding, etc.) under the guidance of a mentor committee. CCR Grants support outstanding translational research into the understanding, detection & treatment of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026.
Conditions / Restrictions	CCR Grants will be awarded to a single Principal Investigator (PI). Applicants must have a doctoral degree, including M.D., Ph.D., Dr.P.H., D.O., or equivalent. Applicant must currently hold a full-time faculty appointment or have a formal offer letter from the Institution that confirms position and start date by the Application due date (October 17, 2018).

	<p>Applicants must not have held any faculty appointment, including non-tenure and tenure track appointments combined, for more than a total of 5 years by the Application due date.</p> <p>Applicants may only submit ONE LOI per funding cycle.</p> <p>Applicants must not simultaneously hold any other Grant awarded by Susan G. Komen. Such Grants must end within 3 months of receiving a Notification of Intent to Fund or the funding will be withdrawn.</p> <p>Applicants must not currently be or have been a PI on an existing NIH R01 grant or their equivalent as of the date of Award Notification (April 15, 2019).</p> <p>Applicants must conduct the proposed research and training at the Lead Mentor's institution, which may be located anywhere in the world.</p> <p>Applicants must have adequate space and facilities to conduct the proposed research and protected time for research, as verified by the Letter of Institutional Support.</p> <p>Applicants must ensure that all past and current Komen-funded Grants are up to date and in compliance with all Komen requirements; e.g., progress report submissions, IRB approvals, etc. by the Application due date (October 17, 2018).</p> <p>Applicants are not required to be a U.S. citizens or residents. Applicants located outside of the U.S. or proposing research to be conducted outside of the U.S. will also be considered eligible if they clearly state in the Letter of Intent how the proposed research will lead to a reduction in breast cancer deaths.</p> <p>Applicants must propose a Mentor Committee, typically consisting of 3-5 mentors, including the Lead Mentor and a Patient Advocate Mentor. The primary purpose is to provide the research, scientific, clinical, management, and leadership guidance necessary to foster the Applicant's career advancement and assist in the successful development of the proposed Research Project. All members of the Mentor Committee are not required to currently conduct breast cancer research but should provide expertise, leadership or support to the Applicant & Project.</p> <p>Lead mentor of any nationality must hold a full-time faculty appointment at the same institution as the applicant and is considered to be an expert in breast cancer research, but in the absence of this expertise at least one member of the Mentor Committee must fulfill this requirement.</p> <p>Patient Advocate Mentor provides the patient perspective in the design and implementation of both Research Projects and Career Development Plans. If an Applicant is invited to submit an Application, a Patient Advocate Mentor must be named as Key Personnel and a member of the Mentor Committee for submission of the Application (October 17, 2018). While Applicants are strongly encouraged to name a Patient Advocate Mentor in the Letter of Intent (August 1, 2018). Patient Advocate Mentors can (i) be involved early in the development of the Research Project to provide input about its relevance and impact to patients; (ii) review the Letter of Intent to help articulate the importance of the Research Project to breast cancer patients; (iii) be invited to attend lab meetings or give presentations to provide the patient point of view and a different perspective to the Research Project; (iv) be included in clinical trial development, provide input on potential barriers to accrual, and help develop patient education materials; (v) assist in disseminating the importance of the results of the Research Project using lay language that will be better understood by the general public.</p> <p>As a Patient Advocate Mentor can serve those who (i) have been diagnosed with breast cancer; have a known genetic mutation; or have a strong personal connection or experience with breast cancer (i.e., family, friend, caregiver); (ii) can represent a collective breast cancer patient/survivor perspective (i.e., insights and experiences of other breast cancer survivors); (iii) have a basic understanding of the science of breast cancer and are involved in the broader breast cancer research advocacy community; (iv) do not have a conflict of interest (i.e. a financial or personal relationship) that may bias their patient perspective. See the webinar: https://www.youtube.com/watch?v=adJ0MCQGbj8&feature=youtu.be</p> <p>Host institutions must agree to adhere to Komen's Policies and Procedures for Research and Training Grants, which may be downloaded along with the Letter of Intent Templates in proposalCENTRAL, https://proposalcentral.altum.com.</p> <p>Budget is not required to be submitted with the Letter of Intent.</p>
Proposal consists of	<p>I. Online submission of a Letter of Intent (LOI) via proposalCENTRAL system, https://proposalcentral.altum.com (Wed 01 Aug 2018 13:00 EST)</p> <p>1) Online basic information: (i) title page (max 81 characters); (ii) download templates & instructions; (iii) enable other to access the proposal; (iv) applicant/PI information pre-populate from the Professional Profile Page; (v) institutions & contacts; (vi) key personnel include Lead Mentor, Patient Advocate Mentor(s), Committee Members, and major collaborators who are integral to the execution of the research plan (applicant)</p> <p>2) Letter of Intent: (i) Title (max 81 characters); (ii) Research Plan describes the research question and how the project will lead to a reduction in breast cancer deaths by 2026. A clear and concise statement of the research question, hypothesis(es), and specific aims of the project</p>

	<p>must be included; (iii) Impact Statement describes how the proposal and specific aims will directly address the goals of the CCR research focus, Conquering Metastatic Breast Cancer, and how the project will lead to a reduction in breast cancer deaths by 2026; (iv) name a Mentor Committee consisting of 3–5 mentors, including a Lead Mentor and a Patient Advocate Mentor (use template, max 1 page, upload in PDF, “Surname_LOI”) (applicant & Lead Mentor)</p> <p>3) Applicant’s Biosketch: (i) Personal Statement; (ii) Positions & Honors; (iii) Contributions to Science; (iv) Additional Information: Research Support, Scholastic Performance (use template, max 5 pages, upload in PDF, “Surname_Biosketch”) (applicant)</p> <p>4) Letter of Institutional Support submitted and signed by the department chair, on Institution Letterhead: (i) confirmation of the date and specific title of Applicant’s current faculty appointment, or confirmation of a pending faculty appointment; (ii) the total number of years the Applicant has held a non-tenure or tenure track faculty appointment at the current institution and all previous institutions, if applicable (upload in PDF, “Surname_Letter of Institutional Support”) (Lead Mentor & host institution)</p> <p>II. Online submission of an application via proposalCENTRAL system, https://proposalcentral.altum.com (Wed 17 Oct 2018 13:00 EST)</p>
Evaluation criteria	<p>Outstanding translational research into the understanding, detection, diagnosis & treatment of metastatic breast cancer which will lead to a reduction in breast cancer deaths by 2026. Appropriate studies for this program include, but are not limited to:</p> <ul style="list-style-type: none"> ○ Development of novel treatment strategies for existing metastatic disease. This could include applications that address drug resistance, research that investigates approaches to improve delivery of existing therapies to metastatic disease, as well as studies focused on the immune system and potential vaccine strategies. ○ New approaches to detect recurrence and strategies to prevent or arrest metastasis. This could include studies that focus on the mechanisms of metastatic growth. ○ Correlative studies of existing clinical trials for metastatic breast cancer, including analysis of biopsies and other patient samples. Such studies should leverage existing clinical trials to advance the understanding and treatment of metastatic breast cancer, including early recurrence. ○ Investigating disparities leading to a higher burden of metastatic disease in certain populations, including biological or social causes, and/or interventions that eliminate disparities in metastatic breast cancer patients. ○ Utilizing data science methods to better understand and treat metastatic breast cancer.
Research areas	<p>Metastatic breast cancer disparities research is defined as research investigating the biologic, behavioral, social and systems contributors to late-stage (metastatic) breast cancer in population groups affected by breast cancer disparities. This may include (i) identification, validation and testing of biological and/or socioeconomic factors that contribute to breast cancer disparities in metastatic breast cancer; (ii) identification of health services and public health interventions that address the causes of disparities in care and outcomes across population groups in metastatic breast cancer.</p> <p>Data science to better understand & treat metastatic breast cancer includes artificial intelligence & other analytical methods applied to data aggregated from multiple sources (Electronic Health Records, other clinical data, administrative databases, large data repositories, genomics and other -omics data, etc.).</p> <p>Basic science studies focused on the mechanisms of breast cancer cell motility and broad exploratory (i.e. “hypothesis generating”) studies are NOT appropriate for this program.</p>
Call workshop	None
IOCB contact	<p>Please inform the IOCB Project Office about your intention to apply. Do not hesitate anytime to contact us for consulting, discussion or help. projectoffice@uochb.cas.cz, +420 220 183 266</p>
Download documents	<p>2018-07-02_IOCB_call_Komen-CCR-Grants_D2018-08-01</p> <p>Komen CCR Grants 2019 LOI guidelines</p> <p>Komen CCR Grants 2019 LOI personnel definitions</p> <p>Komen CCR Grants 2019 Letter of Intent Template</p> <p>Komen CCR Grants 2019 Biosketch Template</p> <p>Komen Policies & Procedures FY2018</p>